MIGUEL ÁNGEL BERCIANO GUERRERO – ENSAYO CLINICO COMERCIAL – ALKERMES INC
A Phase 2, Open-label, Multicenter, Cohort Study of Nemvaleukin Alfa (ALKS 4230) Monotherapy Administered Subcutaneously in Patients With Advanced Cutaneous Melanoma or Intravenously in Patients With Advanced Mucosal Melanoma Who Have Previously Received Anti-PD-[L]1 Therapy – ARTISTRY-6
by prodriguez | Jul 3, 2024 | Clinical Trials, Ensayos Clínicos - CIMO-02 | 0 comments